1-3 of 3
Blake J Bartlett, PhD
Close
Sort by
Journal Articles

Investigation of the Association Between Treatment Effects On Progression Free Survival and Overall Survival in Multiple Myeloma Using Data From Published Literature

Bin Zhang, Shannon Cartier, Virginia Rosen, April Teitelbaum, Ying Zhang, Blake J Bartlett, PhD, Glenn Kroog, MD, Pralay Mukhopadhyay, Samuel Wagner, PhD, RPh
Journal: Blood
Blood (2012) 120 (21): 4241.
https://doi.org/10.1182/blood.V120.21.4241.4241
Published: 2012
Journal Articles

Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,

Sundar Jagannath, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, Thierry Facon, MD, Ravi Vij, MD, Marc S Raab, MD, PhD, Darrell J. White, MD, Min-Hui Wang, PhD, Teresa Parli, MD, Blake J Bartlett, PhD, Anil K Singhal, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 3968.
https://doi.org/10.1182/blood.V118.21.3968.3968
Published: 2011
Journal Articles

Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.

Lei Wu, MD, Mary Adams, MS, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, Blake J. Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 4885.
https://doi.org/10.1182/blood.V110.11.4885.4885
Published: 2007